CFM
RIGL icon

Catalyst Funds Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Catalyst Funds Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,000
Closed -$378K – 662
2025
Q1 		$378K Sell
21,000
-2,700
-11% -$54.8K 0.1% 228
2024
Q4 		$399K Buy
23,700
+21,000
+778% +$403K 0.1% 181
2024
Q3 		$43.7K Buy
+2,700
New +$31.7K 0.01% 847

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Catalyst Funds Management's RIGL Position: Q2 2025 in Review

Catalyst Funds Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2025, closing a stake of 21,000 shares — an estimated $378K sold.

Catalyst Funds Management first reported a position in RIGL in Q3 2024 and held it in 3 quarters. The position peaked at $399K in Q4 2024. 125 funds tracked by Wall St. Rank hold RIGL as of Q2 2025.

  • Catalyst Funds Management reported no remaining Rigel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 21,000 Rigel Pharmaceuticals shares in Q2 2025, an estimated $378K.
  • Catalyst Funds Management first reported a position in Rigel Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Rigel Pharmaceuticals position peaked at $399K in Q4 2024.
  • 125 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2025.

Based on Catalyst Funds Management's 13F filing for Q2 2025, filed 12 Aug 2025.